A detailed history of Virtu Financial LLC transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Virtu Financial LLC holds 75,126 shares of ATOS stock, worth $96,161. This represents 0.01% of its overall portfolio holdings.

Number of Shares
75,126
Previous 83,941 10.5%
Holding current value
$96,161
Previous $151,000 41.06%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$1.03 - $2.1 $9,079 - $18,511
-8,815 Reduced 10.5%
75,126 $89,000
Q1 2024

May 20, 2024

BUY
$0.8 - $1.89 $67,152 - $158,648
83,941 New
83,941 $151,000
Q3 2023

Nov 14, 2023

SELL
$0.74 - $1.35 $4,502 - $8,214
-6,085 Reduced 7.01%
80,728 $59,000
Q2 2023

Jul 27, 2023

BUY
$0.6 - $1.28 $52,087 - $111,120
86,813 New
86,813 $109,000
Q4 2021

Feb 17, 2022

SELL
$1.6 - $3.27 $117,646 - $240,439
-73,529 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$2.89 - $6.4 $158,675 - $351,392
54,905 Added 294.81%
73,529 $240,000
Q2 2021

Sep 17, 2021

SELL
$1.52 - $8.62 $385,035 - $2.18 Million
-253,313 Reduced 93.15%
18,624 $118,000
Q1 2021

May 19, 2021

SELL
$0.92 - $4.33 $3,097 - $14,579
-3,367 Reduced 1.22%
271,937 $574,000
Q4 2020

Feb 24, 2021

BUY
$0.85 - $2.43 $234,008 - $668,988
275,304 New
275,304 $262,000
Q2 2020

Aug 07, 2020

SELL
$1.04 - $4.05 $15,295 - $59,563
-14,707 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$1.25 - $1.87 $18,383 - $27,502
14,707 New
14,707 $23,000
Q2 2019

Aug 13, 2019

SELL
$2.03 - $3.58 $73,709 - $129,989
-36,310 Closed
0 $0
Q1 2019

Apr 12, 2019

SELL
$1.11 - $7.07 $37,288 - $237,502
-33,593 Reduced 48.06%
36,310 $128,000
Q4 2018

Jan 16, 2019

BUY
$0.92 - $1.67 $51,578 - $93,626
56,064 Added 405.12%
69,903 $71,000
Q3 2018

Nov 13, 2018

BUY
$1.47 - $2.78 $20,343 - $38,472
13,839 New
13,839 $24,000

Others Institutions Holding ATOS

About ATOSSA THERAPEUTICS, INC.


  • Ticker ATOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,624,000
  • Market Cap $162M
  • Description
  • Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...
More about ATOS
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.